RxDoctor Payments Data

Timothy Darnell, DO

Infectious Disease · Winston Salem, NCNPI 1467678979

Payments from drug & device makers

$3,510in general payments, 2019–2025

Across 181 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$661
  • AbbVie$281
  • Insmed, Inc.$274
  • Merck$247
  • Takeda Pharmaceuticals U.S.A., Inc.$185
  • plus $570 from 11 others

What the payments were for

  • Food & beverage$3,34695%
  • Education$1645%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,510 in reported general payments places this provider in the 70th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$60,961
Medicare patients
175
Services billed
561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala84$330,270
DovatoDolutegravir Sodium/Lamivudine71$218,354
TriumeqAbacavir/Dolutegravir/Lamivudi27$97,644
JulucaDolutegravir/Rilpivirine26$89,492
GenvoyaElviteg/Cob/Emtri/Tenof Alafen18$82,934
DescovyEmtricitabine/Tenofov Alafenam34$74,552
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$67,762
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$61,359
PrezcobixDarunavir/Cobicistat20$48,561
TivicayDolutegravir Sodium12$26,547
ErtapenemErtapenem Sodium36$17,877
Darunavir11$17,427
Daptomycin55$13,406
Cefepime Hcl35$9,606
Vancomycin Hcl27$5,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$661$487,756136 claims
Viiv Healthcare CompanyDovato, Triumeq, Juluca, Tivicay$1,291$432,038136 claims
Janssen Products, LPSymtuza$70$61,35913 claims
Johnson & JohnsonPrezcobix$17$48,56120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →